Mississippi Clinical Trials Report — April 2026

For Mississippi residents considering participation in clinical research, April 2026 presents a critical window to act on studies nearing their enrollment deadlines. A total of 20 clinical trials across the state are scheduled to close within the next 90 days. This includes opportunities for healthy volunteers, with 2 of these rapidly closing studies still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing a range of health conditions also face impending deadlines to join research. Trials focused on various conditions, from inflammatory diseases to specific types of cancer and kidney issues, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Acute gouty arthritis
• Age-related macular degeneration
• Anatomic stage II breast cancer AJCC v8
• Anatomic stage III breast cancer AJCC v8
• Atopic dermatitis
• Attention-deficit/hyperactivity disorder
• Avascular necrosis
• Chronic granulomatous disease (CGD)
• Chronic kidney disease
• Chronic kidney disease, receiving dialysis

These trials represent diverse areas of medical inquiry, offering participants the chance to contribute to understanding and treating conditions that affect many Mississippians. The urgency to enroll is particularly high for these studies, as recruitment windows are closing.

A Significant New Opportunity in Oncology

This month, Mississippi welcomes one notable new clinical trial, a significant Phase 3 study sponsored by Incyte Corporation. This trial, NCT07522073, is titled "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." It aims to enroll 588 participants globally, with sites in Mississippi contributing to this important research.

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy when combined with or without INCB161734 in individuals diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) that carries a specific KRAS G12D mutation. Pancreatic cancer is a challenging disease, and new treatment approaches are critically needed. A Phase 3 trial like this represents a late stage of drug development, where the investigational treatment is compared against current standard care to determine if it offers superior benefits.

While this is a highly significant trial for those affected by this specific cancer, it is important to note the overall trend in new trial openings this month. April 2026 saw only 1 new trial open in Mississippi, a notable decrease from the 4 trials that launched in March 2026. Looking back over the past six months, the number of new trials has fluctuated, with 5 in November 2025, 9 in December 2025, 1 in January 2026, 4 in February 2026, and 5 in March 2026. This month's single new opening underscores the importance of staying informed about every new research opportunity as it arises.

Healthy Volunteers: Act Now for Closing Trials

For individuals without a specific medical condition who are interested in contributing to medical research, opportunities exist, though they are limited among the newest trials. As mentioned, 2 of the 20 trials closing within the next 90 days are actively seeking healthy volunteers. This is a direct call to action for those who wish to participate in research and contribute to scientific understanding before these specific studies conclude enrollment.

Statewide, there are currently 26 clinical trials recruiting healthy volunteers across Mississippi. These studies play a crucial role in establishing baseline data, testing new diagnostic tools, or evaluating the safety of new treatments in healthy populations. However, the single new trial launched this month does not accept healthy volunteers, making the existing 26 trials, and especially the 2 closing soon, the primary avenues for those without specific conditions.

Mississippi's Research Footprint: Where to Find Trials

Mississippi continues to be an active hub for clinical research, with a total of 364 clinical trials currently recruiting participants. These studies are spread across 38 cities and involve 227 research sites throughout the state. This broad distribution ensures that research opportunities are accessible to a significant portion of the population, beyond just major metropolitan areas.

The single new trial this month, the Incyte Corporation oncology study, opened in Hattiesburg. While this month's new trial activity is concentrated in one city, the overall landscape of recruiting trials remains geographically diverse. This means that individuals in various parts of Mississippi may find research opportunities closer to home, reducing travel burdens for participation.

Who Can Participate: Eligibility and Demographics

Clinical trials often have specific eligibility criteria to ensure the safety of participants and the integrity of the research. The new Incyte Corporation trial for metastatic pancreatic ductal adenocarcinoma is a drug trial and is open to older adults. This is a common demographic for many chronic and age-related conditions, highlighting the importance of including this population in medical research.

Among the new trials this month, there are no studies specifically designed for children, nor are there any designated as female-only or male-only. This means that while the new opportunities are focused on a specific adult patient population, the broader landscape of 364 recruiting trials across Mississippi likely offers diverse eligibility criteria for various age groups and genders. Potential participants are always encouraged to review the detailed eligibility requirements for any trial they are considering.

As we move further into spring, the focus will likely remain on the ongoing enrollment in the existing 364 trials and the critical deadlines for the 20 studies closing soon. Researchers in Mississippi continue their vital work, and patient and healthy volunteer participation remains essential for advancing medical knowledge and improving health outcomes for everyone.